During Wednesday’s current trade, Interpublic Group of Companies Inc (NYSE:IPG)’s shares gained 0.29%, to $20.58.
Interpublic Group (IPG) declared that the company`s Board of Directors has declared a quarterly dividend on IPG common stock of $0.12 per share, payable on June 16, 2015 to holders of record at the close of business on June 2, 2015.
The Interpublic Group of Companies, Inc. provides advertising and marketing services. The company operates in two segments, Integrated Agency Networks and Constituency Administration Group. It offers consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines.
TE Connectivity Ltd (NYSE:TEL)’s shares jumped 0.66% to $69.65, during the current trading session Wednesday’s.
TE Connectivity Ltd. (TEL) declared that the $0.33 per share quarterly dividend for the third fiscal quarter of 2015 will be payable on June 12, 2015, to shareholders of record at the close of business on May 29, 2015. The dividend was approved by shareholders at the company’s annual general meeting held on March 3, 2015.
TE Connectivity Ltd., together with its auxiliaries, designs and manufactures connectivity and sensors solutions. It operates through four segments: Transportation Solutions, Industrial Solutions, Network Solutions, and Consumer Solutions. The Transportation Solutions segment offers electronic components, counting terminals and connectors, relays, and sensors, in addition to application tooling, wire and heat shrink tubing, and other custom-engineered solutions for the automotive market, such as industrial and commercial vehicle, and hybrid and electric vehicle markets.
In a mid-morning trade, Immunomedics, Inc. (NASDAQ:IMMU)‘s shares climbed 1.50%, to $4.07.
Immunomedics, Inc., (IMMU) declared an interim analysis of a mid-stage clinical study showed that its first-in-class antibody-drug conjugate (ADC), labetuzumab govitecan, produced encouraging survival results in patients formerly treated with at least one prior irinotecan-containing regimen for their metastatic colorectal cancer (mCRC).
For the 33 patients who received the ADC at the 8 or 10 mg/kg dose levels, the interim median progression-free survival (PFS), a measure of the length of time the patient is living without their disease getting worse from the starting of their labetuzumab govitecan treatments, was 4.4 months, with 22% of these patients still benefiting from their cancer not progressing.
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs comprise epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer.
North Atlantic Drilling Ltd. (NYSE:NADL), during its Wednesday’s current trading session declined -1.47% to $1.34.
North Atlantic Drilling Limited (NADL) reports first quarter 2015 results.
- North Atlantic Drilling generates first quarter 2015 EBITDA* of $92.4 million
- North Atlantic Drilling reports first quarter 2015 net loss of $11.3 million and loss per share of $0.06
- Seadrill Limited provides guarantees for North Atlantic Drilling’s NOK1.5 billion bond maturing in 2018 and for North Atlantic Drilling’s two secured credit facilities. In exchange, the lenders have agreed to replace North Atlantic Drilling’s financial covenants with Seadrill’s financial covenants
Subsequent events
- North Atlantic Drilling successfully extends the termination date of the Framework Agreement with Rosneft until May 31, 2017
- The Board declares the resignation of Ms. Cecilie Fredriksen and Mr Harald Thorstein as directors of the Company. Ms. Fredriksen and Mr Thorstein are leaving the Board to focus on other responsibilities and activities, counting those in related companies.
- The Board is also happy to declare the appointment of Orjan Svanevik as a Director to fill a vacancy on the Board. Mr. Svanevik is an employee of the Seatankers Group. He was formerly Managing Director for the investment advisory firm, Oavik Capital. Prior to Oavik, he was Head of M&A and a Partner at Aker ASA, and COO and EVP of Kvaerner ASA. Svanevik also worked nearly a decade in corporate advisory and investment banking. He started his career at Schlumberger, where he held various international financial administration positions. Svanevik has an AMP from Harvard Business School and a MBA from Thunderbird.Mr. Svanevik is also a director of Seadrill Limited
North Atlantic Drilling Limited operates as an offshore drilling services contractor in the North Atlantic region. The company provides harsh environment offshore drilling services to the oil and gas industry primarily in Norway and the United Kingdom. As of December 31, 2014, the company owned eight offshore drilling rigs, counting one ultra-deep water drillship, three jack-up rigs, and four semi-submersible rigs comprising one rig under construction. It also has a contract for the construction of one semi-submersible rig.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
